These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. Donat SM; North A; Dalbagni G; Herr HW J Urol; 2004 Feb; 171(2 Pt 1):636-9. PubMed ID: 14713776 [TBL] [Abstract][Full Text] [Related]
23. Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. Shipley WU; Rose MA; Perrone TL; Mannix CM; Heney NM; Prout GR J Urol; 1985 Oct; 134(4):679-83. PubMed ID: 4032570 [TBL] [Abstract][Full Text] [Related]
24. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder. Pham HT; Soloway MS Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909 [TBL] [Abstract][Full Text] [Related]
25. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284 [TBL] [Abstract][Full Text] [Related]
26. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. Solsona E; Iborra I; Dumont R; Rubio-Briones J; Casanova J; Almenar S J Urol; 2000 Sep; 164(3 Pt 1):685-9. PubMed ID: 10953125 [TBL] [Abstract][Full Text] [Related]
27. Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies. Zhang M; Tao R; Zhang C; Shen Z Urology; 2010 Oct; 76(4):902-7. PubMed ID: 20709377 [TBL] [Abstract][Full Text] [Related]